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Abstract
Scale-up of malaria preventive and control interventions over the last decade resulted in
substantial declines in mortality and morbidity from the disease in sub-Saharan Africa and
many other parts of the world. Sustaining these gains will depend on the health system per-
formance. Treatment provides individual benefits by curing infection and preventing pro-
gression to severe disease as well as community-level benefits by reducing the infectious
reservoir and averting emergence and spread of drug resistance. However many patients
with malaria do not access care, providers do not comply with treatment guidelines, and
hence, patients do not necessarily receive the correct regimen. Even when the correct regi-
men is administered some patients will not adhere and others will be treated with counterfeit
or substandard medication leading to treatment failures and spread of drug resistance. We
apply systems effectiveness concepts that explicitly consider implications of health system
factors such as treatment seeking, provider compliance, adherence, and quality of medica-
tion to estimate treatment outcomes for malaria case management. We compile data for
these indicators to derive estimates of effective coverage for 43 high-burden Sub-Saharan
African countries. Parameters are populated from the Demographic and Health Surveys
and other published sources. We assess the relative importance of these factors on the
level of effective coverage and consider variation in these health systems indicators across
countries. Our findings suggest that effective coverage for malaria case management
ranges from 8% to 72% in the region. Different factors account for health system inefficien-
cies in different countries. Significant losses in effectiveness of treatment are estimated in
all countries. The patterns of inter-country variation suggest that these are system failures
that are amenable to change. Identifying the reasons for the poor health system perfor-
mance and intervening to tackle them become key priority areas for malaria control and
elimination policies in the region.
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Introduction
Scale-up of malaria preventive and control interventions over the last decade resulted in sub-
stantial declines in mortality and morbidity of the disease in sub-Saharan Africa and many
other parts of the world [1–4]. As many as 274 million cases and 1.1 million deaths were pre-
vented by the focused effort of the national malaria control programs and global community
over the last decade [4]. Sustaining these gains will depend not only on the availability of re-
sources but also on the health systems performance [5]. Treatment provides individual benefits
by curing infection and preventing progression to severe disease as well as community-level
benefits by reducing the infectious reservoir and averting the emergence and spread of drug re-
sistance [4]. Understanding the extent of the health benefit achieved with malaria case manage-
ment has thus critical implications for malaria control and elimination programs.
Current global guidelines for malaria case management require prompt parasitological con-
firmation by microscopy or RDTs in patients suspected of malaria; pending diagnostic confir-
mation the recommended treatment for uncomplicated P. falciparummalaria includes at least
3 days of therapy with artemisinin-based combination drugs (ACT) [6]. Artemether lumefan-
trine (ALU) is the most commonly recommended first-line treatment across the SSA [4]. The
drug provides fast relief of symptoms and enables a nearly 100% clearance of parasitaemia if
treated within 24 hours of onset of fever. Despite availability of efficacious therapy many pa-
tients with malaria do not have access to it or delay appropriate treatment seeking, and provid-
ers do not always comply with treatment guidelines, so patients do not necessarily receive the
correct regimen or instructions. Even when the correct regimen is administered some patients
will not adhere and yet others will be treated with counterfeit or otherwise substandard medi-
cation leading both to treatment failures and potentially also to the spread of drug resistance.
The effectiveness of malaria case management depends therefore on a number of health sys-
tems factors that should be taken into account when assessing the impact of control strategies.
One important measure of the effectiveness of malaria service delivery is the systems effective-
ness [7,8], which measures the proportion of clinical events that are effectively treated by the
formal health services that offer interventions by health professionals (including hospitals,
health centers, and community health workers). A second measure, the effective coverage
[9,10] includes in addition the effects of self-treatment, or of treatment obtained from un-
trained drug sellers or other informal providers. Although informal providers should comply
with national guidelines for case management, in practice compliance in the informal sector is
generally lower than with formal provision. Effective coverage is nevertheless higher than sys-
tems effectiveness because informal provision adds more providers and therefore higher access
into the calculus of effectiveness, even though such provision may be of lower quality.
Supply side determinants of these metrics include access to treatment, diagnosis, staff train-
ing, and availability of antimalarials at the facility level [11–16]; on the demand side patient
awareness and perception of illness, affordability of treatment and adherence to the drug regi-
men are commonly considered [17–19]. Analyses generally focus on the limits to systems effec-
tiveness of delivering ACTs to febrile or malaria patients through the public sector with
estimates generated for the region as a whole [11,20] and for a given country
[12,13,18,19,21,22]. These evaluations reveal large inefficiencies in malaria service delivery
across the endemic countries. Illustrative of the magnitude are findings from [23] that demon-
strated decay from 98%—theoretical efficacy of ACTs—to just about 38%—effectiveness- by
the time the medication is administered. Similarly, low levels of effective coverage were esti-
mated for Tanzania of about 5% [12], Ghana—31 to 42% [19], and Zambia—25% [18].
The geographic coverage of these evaluations remains limited with meaningful cross coun-
try comparisons hindered by differences in methodological approaches and adopted
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framework; in particular the choice of parameters considered for the health system factors var-
ies greatly across the studies. Focusing on public sector and ACT therapy these analyses repre-
sent only a fraction of malaria case management services delivered in SSA countries. Frequent
stock-outs of ACTs[24], presence of non-ACT antimalarials[16,25], heavy reliance on informal
care providers[4] as well as concerns about the quality of antimalarial drugs[26,27] in the re-
gion call for a more comprehensive measure of effective coverage for the sector.
In this article we estimate performance of malaria case management in Sub-Saharan African
countries focusing on clearance of the infection among malaria patients. In other words, we are
primarily interested in the proportion of malaria fevers that are cured by the prevailing health
system and further in identifying the sources of inefficiency in service delivery and their relative
importance for malaria patient outcomes. We produce a consistent measure of effective treat-
ment that captures both public and private health care providers and treatments with drugs
other than the first-line therapy for each of the 43 high malaria burden countries.
Methods
Estimation framework
The methodology to estimate the performance of case management of malaria fever is based
on a set of indicators that capture the key factors that determine the effectiveness of treatment.
The analysis is based on a decision tree (Fig 1) which is an extension of our previously pub-
lished model for case management of uncomplicated malaria [28]. The entry point to the
model is a malaria fever episode, from where the branches move to describe treatment seeking,
and then by level of care compliance with the recommended first-line antimalarial therapy. We
include adherence with the drug regimen and its cure rate, which in turn is modelled as a func-
tion of drug quality, resistance, and clinical efficacy. Combining these parameters, we obtain a
measure of effective coverage (E) defined here as the expected probability of clinical and parasi-
tological cure for an episode of malaria fever. Algebraically the effective coverage (E) is express-
ed as a function of health seeking (A) scaled down with the weighted average cure rate of an
antimalarial treatment (Tpd) across different drugs (d) and providers (p) (Eq (1)):
E ¼ Að
X
p
Pp
"X
d
DpdHpdTpd
#
Þ; ð1Þ
where
X
p
Pp ¼ 1,
X
d
Dpd ¼ 1
A is the proportion of malaria fevers seeking care;
Pp is the proportion of care-seeking malaria fever episodes accessing provider p;
Dpd is the proportion of malaria fever episodes treated by provider p with antimalarial thera-
py d;
Hpd is the proportion of fever cases treated with drug d by provider p that adhere with the
regimen;
Tpd is cure rate of antimalarial therapy d obtained from provider p;
Where the cure rate (Tpd) accounts for treatment failure due to suboptimal quality of medi-
cations (Qpd), resistance (Rpd), and clinical efficacy of the antimalarial therapy (Cd) (Eq (2)):
Tpd ¼ ð1 QpdÞð1 RdÞð1 CdÞ; ð2Þ
where Qpd, Rd and Cd are 0 and 1
Qpd is the proportion of antimalarial treatments d obtained from provider p that are coun-
terfeit or of substandard quality;
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Rd is the proportion of episodes caused by parasites resistant to drug d;
Cd is the parasitological failure rate of sensitive parasites for drug d;
As an extension this framework can be applied to evaluate the probability that the health
system treats a fever effectively and in line with the official policy (the right hand branch in
Fig 1). Here the systems effectiveness refers to the performance of the formal health system,
and is therefore:
S ¼ APfDfaHfaTfa; ð3Þ
where f corresponds to formal health services and a to the recommended first-line antimalarial
treatment (see Table 1 and Fig 1).
Data
The definitions, data sources, and key assumptions for each parameter defined in the model
are outlined in Table 1 and further by country in S2 Table. Service indicators related to access
and type of care provider, compliance and adherence are measured primarily from the Demo-
graphic and Health Surveys (DHS) [29–31] and the Multiple Indicator Cluster Surveys (MICS)
[32]. These nationally representative household surveys are used extensively for research in
low- and middle-income settings [33]. Across the surveys, data are collected from mothers and
carers of children under the age of 5; malaria module questions pertain to service use for the
last episode of fever and/or cough within a two weeks recall [31]. While there is a high degree
of comparability between the survey instruments, the data sources differ in scope and coverage
Fig 1. Decision Tree Model for Case Management of Uncomplicated Malaria.
doi:10.1371/journal.pone.0127818.g001
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resulting in some differences in estimates [34]. Of the two the DHS is a more comprehensive
resource, with the primary purpose of producing monitoring and impact evaluation indicators
at national and regional level; these data allow for a consistent definition of a broader set of in-
dicators considered in this analysis thus we opt for DHS over MICS estimates. Survey data for
more recent MICS (round 4, corresponding to data collection years 2010–2011) were available
only for a subset of counties at the time of the analysis with most country data presented in a
summary report form. In the latter definitions of coverage indicators are narrower than nose
adopted in our model with health seeking defined as a proportion of children under five years
of age with fever receiving antimalarial medicines. Using the reports to fill in gaps in DHS data
will result in lower estimates of coverage; we turned to these data only when no other data were
available and used more dated DHS surveys if coverage estimates were higher than those re-
ported in more recent MICS.
We assume health seeking and choice of care provider for malaria related fever is the same
across febrile conditions; thus access to malaria case management and source of treatment as-
sessed as a proportion of all-cause fever cases is deemed representative of malaria fevers.
Table 1. Summary of Definitions, Sources of Data and Key Assumptions on Malaria Service Performance Indicators.
Model Input Nota-
tion
Definition Data Source Core Assumptions Additional comments
Access to any
care provider
A Proportion of <5 fevers for which care
is sought
DHS, MIS,
MICS
Patterns in health seeking
for febrile illness are
representative of malaria
Access to a
formal care
provider
Pp|
p = f
Proportion of access for which care is
sought from formal care provider
DHS Patterns in health seeking
by provider type for febrile
illness are representative of
malaria
Formal provider—treatment based
on diagnosis by a medical
professional- including hospitals,
health centers, community health
worker, etc.
Access to an
informal care
provider
Pp|
p = i
Proportion of access for which care is
sought from informal care provider
DHS Patterns in health seeking
by provider type for febrile
illness are representative of
malaria
Informal provider- treatment based
on self-diagnosis- including
pharmacies, shops, street vendors
etc.
Compliance Dpd|
d = a
Proportion of treated <5 malaria
fevers that receive first-line
antimalarial therapy (ACT)
DHS, MICS,
WMR,
[36,59,74–79]
All malaria related fevers
for which treatment is
sought are treated with an
antimalarial
First-line antimalarial therapy defined
according to country policy
Non-
compliance
Dpd|
d = s
Proportion of treated <5 malaria
fevers that receive antimalarial
therapy other than first-line
medication
DHS, MICS,
WMR,
[36,59,74–79]
All malaria related fevers
for which treatment is
sought are treated with an
antimalarial
Non-compliant treatment with
therapy other than the first-line
medication is proxied with SP
Adherence Hd Proportion of treated <5 malaria
fevers that adhere with the drug
regimen (d = a: first line ACT regimen;
d = s: other)
DHS, [49–
56,80–82]
100% failure rate for
partially adherent
treatments
Adherence with the drug regimen is
defined in terms of days of treatment
Cure rate Tpd Efficacy of antimalarial drugs taking
into account clinical and
parasitological failure rate Cd,
resistance Rd, and incidence of
counterfeit and sub-optimal
formulations Qpd
WMR, [41–
45,83–85],
[46]
100% failure rate for
treatments with sub-optimal
or counterfeit antimalarial
drugs
Clinical efficacy, levels of resistance
and prevalence of sub-optimal or
counterfeit antimalarial drugs are
assumed to be the same across
SSA countries
Effective
coverage
E Proportion of <5 malaria fevers cured Derived Service performance
indicators relate linearly to
treatment outcomes
System
effective-ness
S Proportion of <5 malaria fevers cured
by the formal health system.
Derived Service performance
indicators relate linearly to
treatment outcomes
doi:10.1371/journal.pone.0127818.t001
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We ignored recommendations to use parasitological diagnoses in estimating compliance
with the recommended first-line therapy defined according to country policy [4]. Instead, we
proxy malaria etiology with presumptive diagnosis indicated by prescription of an antimalarial
medication, assuming that fevers treated only for other etiologies were not malaria. Malaria ac-
counts for a variable share of febrile cases across countries depending on the transmission level
[35]. Using presumptive diagnosis is supported by evidence from field trials and national sur-
veillance that show that despite changes in policy to introduce diagnostic tests, symptomatic
treatment remains the norm in most of Africa [19,22,27,36]. An additional argument support-
ing omission of diagnostic coverage in this model is presented by a recent evaluation of recall
bias in DHS/MICS surveys pointing to a particularly poor recall of diagnosis and testing related
to malaria episodes, suggesting the recall data substantially understate both the use of diagnos-
tics and positive test results [37].
Compliance with the recommended first-line treatment is likely one of the most time sensi-
tive indicators in our model, with the change toward ACTs representing a fairly recent inter-
vention with increasing and differential rates of scale-up across countries. Data on compliance
came from 2010–2012 surveys and where not available were filled in with information from
the literature and WMR. To our knowledge there have been no comprehensive studies summa-
rizing evidence on ACT implementation and scale-up across the region, in the absence of
which country 2010–2012 trends on ACT deliveries to public and private sectors and ACT
treatment courses distributed by the National Malaria Control Programs fromWMR[38]
could be used to gauge changes in ACT coverage over the period. The report shows that there
was a large increase in the number of ACTs delivered from 2010 to 2011 in the region primarily
through the Affordable Medicines Facility-malaria(AMFm) initiative subsiding ACTs for pri-
vate and public sector distribution in Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania and
Uganda. For most of these countries 2012 survey data were available; for Ghana, Kenya and
Madagascar estimates were derived from 2010–2011 data that only partially capture these ef-
forts. This is particularly an issue for Madagascar where the number of ACT treatments deliv-
ered increased nearly 7 fold in 2012 compared to 2011. The report also indicates that increased
ACTs procurements from 2011 to 2012 reflect purchases for routine public sector deliveries,
which increased by about 50% over the period while the funding through the AMFm facility
declined slightly. Countries with the highest increase not captured by our data include Ethio-
pia, Mali, Nigeria, Rwanda, and Togo; to the extent that changes in number of ACTs delivered
translate into higher coverage our estimates of effectiveness of malaria of case management are
understated for these countries.
Limited country specific data are available on compliance levels by source of treatment. For
a subset of countries for which these data were collected we estimate that on average 60% of
treatments delivered in formal and about 40% in informal sectors comply with the country pol-
icy. We use the ratio to allocate country level compliance from the World Malaria Report [4] to
formal and informal sectors where the parameter could not be estimated directly from the na-
tional surveys. To streamline the analysis, we proxy all treatments that are non-compliant with
the official first-line therapy with Sulphadoxine-Pyrimethamine (SP).
For a subset of recent DHS surveys “drugs taken for fever/cough” sequence is followed with
a sequence on length of drug administration (number of days (1–7)). Adherence with the ACT
regimen is defined narrowly in our framework in terms of number of days an ACT drug was
taken as reported in these surveys. Other dimensions for adherence to ACT drugs not captured
with this definition could include appropriate dosage, timing of administration, and mode of
administration (i.e. intake of fatty foods to facilitate absorption). Since adherence data from na-
tional surveys are sparse, often with unstable sample sizes due to low ACT uptake, we supple-
mented them with estimates from the research literature (S3 Table). Adherence was imputed
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for countries for which no information on the parameter could be identified by relating adher-
ence data from the literature and the surveys to per capita health care expenditures. Studies of
pharmacokinetics and pharmacodynamics of ALU showed that the last two doses (most likely
to be missed by partially adherent patients) contribute most significantly to elevating lumefan-
trine concentrations to levels necessary to clear all parasitemia with incomplete regimens lead-
ing to increased risk of recrudescence [39,40]. We assume conservatively that patients that
took an ACT drug for at least three days achieved an optimal drug concentration while those
partially adherent remained parasitemic after the treatment.
While representative country level data are routinely collected on health seeking and type of
treatment sought for fever data on other aspects of malaria case management in particular with
respect to drug quality and antimalarial resistance are less ample. An indicator for drug quality
is defined in the model as a proportion of antimalarial medications that are counterfeit or sub-
standard and is populated with estimates from recent systematic reviews (S4 and S5 Tables)
[41–45]. This literature however provides little insight on the quality of antimalarial medica-
tion distributed through public outlets; field studies that explored this aspect have shown that
counterfeit and sub-optimal drugs are largely distributed through private and low level care
providers. We thus assume that authentic formulations are dispensed through the formal facili-
ties; counterfeit and suboptimal formulations are only factored in for treatments obtained from
informal sector. Given limited geographic coverage of these data we applied common values
across countries. Patient outcomes when treated with counterfeit or otherwise substandard
medications are not well understood [26,27], partly because there are various reasons for failure
in quality tests including absence of the API, incorrect API, incorrect dosage of API, and sub-
optimal release of API [26]. Due to lack of general guidance on relating drug quality to clear-
ance of parasitemia, we assumed that treatment with drugs classified as substandard fails to
clear parasitemia.
Antimalarial drug resistance is another key factor undermining efficacy of antimalarial ther-
apy. Parasite resistance to artemisinins—the key compounds in ACTs—has been detected in
the Greater Mekong sub-region but ACTs remain so far efficacious in Sub-Saharan Africa[4].
Consequently 0% resistance to first-line treatment is assumed for the countries sampled. Evi-
dence on parasite drug resistance to non-ACT antimalarials is summarised in [46]. Some of
these country estimates are based on trials conducted as far back as 2000; given the rate of resis-
tance we instead applied a median value of parasitological failure rate of sensitive parasites for
SP from the survey to all countries.
Evidence on clinical efficacy of first-line antimalarial medicines produced in controlled
environments according to standard protocols were obtained from [4]. Mean failure rates at
28 days follow-up for ALU are about 1.96%; while for most countries failure rates are well
below 5%, for Burkina Faso and Malawi the rate is 7%. Failure rates for AS+AQ formulations
are on average about 3.91% with highest failure rates reported in Gabon (13.8%). Two coun-
tries in our sample recommend AS+SP as a first-line treatment for uncomplicated malaria;
failure rates for the combination are reported at 0.5% and 2% for Somalia and North Sudan
respectively.
Estimates of both effective coverage and systems effectiveness populated with survey data
depend on the duration of the recall period. In particular, the probability of prompt (i.e. within
one day) effective treatment (E1) defined as a target in the Roll Back Malaria Global Malaria
Action Plan [47] is substantially lower than the effective coverage based 14-day recalls (E14)
[48]. S2 Fig and S1 File provide the algorithm and national-level estimates of E1. Elsewhere in
the paper the term effective coverage (E) refers to E14, in line with the widespread use and avail-
ability of survey data with 14 day recall periods.
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Results
Malaria service performance indicators
Estimates of malaria service performance indicators for the 43 Sub-Saharan African countries
are reported in S1 Table and are summarized graphically in Fig 2.
Access to malaria case management. Overall health seeking for malaria related fever is
relatively high across the region; over half of fevers are treated in either formal or informal set-
tings (median 59%, IQR 50%–84%). Access to malaria case management is lowest in Somalia,
South Sudan, Ethiopia, Togo, and Central African Republic where less than a third of malaria
cases receive any care. Uganda and Nigeria are the two countries with the highest reported
level of treatment of about 84%. When treatment is sought, with a few exceptions, reliance on
formal care providers is ubiquitously high across the region; about 80% of fever cases are treat-
ed in the formal medical sector (median 78%, IQR 50%–91%). An outlier is Chad where we es-
timate that only 17% of treatments are obtained from formal health care providers. Informal
outlets are also the primary source of care for malaria related fevers in Nigeria and Niger: over
half of fever cases for which care is sought are treated informally in these countries.
Provider compliance and patient adherence. Compliance with the recommended first-
line medication for uncomplicated malaria remains low with less than a third of fevers treated
according to the national guidelines (median 28%, IQR 12%–59%). Only a handful of countries
achieved a near perfect compliance with the first-line therapy including Botswana, Malawi,
Rwanda, Sao Tome and Principe, Somalia, and Zambia: about 90% of fevers are treated with
the first-line antimalarial in these countries. When treated with an ACT we find that patients
generally adhered with the drug regimen; over 80% of patients completed the recommended
3-day course (median 81%, IQR 71%–84%).
Drug quality and resistance. Based on the literature review we estimate that on average
17% of ALU purchased from pharmacies, shops, or other informal sources are of substandard
or poor quality with a range between 0 and 62%. A much higher prevalence of counterfeits is
estimated for SP with a mean of 33% and a range between 0 to 66%. While ACTs remain effec-
tive within the Sub-Saharan Africa, resistance to non-ACT antimalarials is estimated within
the 20 to 69% range across the region; when estimating effective coverage we took the midpoint
and assumed that on average SP treatment fails in 40% of cases.
Cure rate. The overall cure rate of antimalarial drugs is estimated at about 66% (median
65%, IQR 53%-80%). Given the paucity of data on the key parameters that contribute to esti-
mation of the cure rate, the variation between countries is driven by the share of treatments ob-
tained from formal care providers. Whereas ACT resistance is not yet important in Africa,
fevers treated in informal setting including markets, shops, and relatives are less likely to re-
ceive the official first-line antimalarial and more likely to receive antimalarial medication that
is counterfeit or otherwise substandard medication. We estimate average antimalarial drug
cure rate at or below 60% for malaria fevers treated in Chad, Democratic Republic of the
Congo, Equatorial Guinea, Mauritania, South Sudan, and Central African Republic.
Overall effective coverage and system effectiveness
Effective coverage of malaria case management varies from 7% in Somalia to as high as 71% in
Botswana; only about 40% of fevers are managed effectively in the region (Fig 3; S1 Table). Ef-
fective coverage is particularly low in a cluster of countries in the North Eastern part of the con-
tinent including Somalia, South Sudan, Chad, Ethiopia, Central African Republic and North
and South Sudan; slightly over 10% of fever cases are treated effectively in these countries. Fo-
cusing on the performance of formal care providers we find that less than 6% of malaria fevers
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Fig 2. Effective Coverage and Malaria Service Performance Indicators by Country (%). Labeled on the
axis are: E Effective coverage; A Access to any care provider; Pf Access to a formal care provider; Dact
Compliance with the first-line antimalarial treatment;H Adherence; TCure rate. Labels for country ISO3
codes are listed in the S1 Table.
doi:10.1371/journal.pone.0127818.g002
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are managed according to the national guidelines in the region. Systems effectiveness ranges
from less than 1% in Chad and South Sudan to at most 60% in Botswana, Sao Tome and Prin-
cipe, and Uganda.
Fig 3 illustrates the large gap between access to malaria case management (access) and cure
with the treatment obtained (effective coverage). While on average 60% of fever cases seek
treatment, only a third clear parasitemia; that is about half of the potential gain from treatment
is lost to inefficiencies. By far the most dramatic difference between access and treatment out-
comes is found in Nigeria where 84% of malaria fevers accessed a care provider; however less
than 32% of malaria fevers were cured in this country. As a percent of fevers treated, effective
coverage is lowest in Chad where less than a third of treatments are effective; a similarly low ef-
fectiveness of malaria case management is estimated for Nigeria, Equatorial Guinea, Cote
d’Ivoire, the Democratic Republic of the Congo, Guinea, Cameroon, Benin, North Sudan,
Madagascar, and Mauritania where less than half of the treatments result in a cure. We find the
highest effective coverage in Botswana, Sao Tome and Principe, Angola, Rwanda, Uganda, and
Zambia with over three fourths of all malaria related fevers treatments effective.
Based on the framework adopted in this analysis effective coverage is necessarily higher
than system effectiveness (S3 Fig), because the former includes the contribution of informal
providers, while the latter represents the effectiveness of the formal health system only. In gen-
eral, the difference between the metrics is less in countries with high effectiveness (in particular
Botswana) than in countries where effectiveness is lower. This difference is clearly driven by
the data and assumptions that imply that treatment provided by the informal system is of
worse quality on several of the indicators. An important example is Nigeria, for which we
Fig 3. Effective Coverage (E) and Access to Any Provider (A) by Country (%). Dashed lines starting with
a 45 degree angle and steeper illustrate the ratio of fever episodes treated effectively (Effective Coverage)
over episodes for which treatment was sought (Access). Labels for country ISO3 codes are listed in the S1
Table.
doi:10.1371/journal.pone.0127818.g003
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estimate relatively high access, but poor compliance, associated with a low proportion of pa-
tients accessing formal facilities.
Impact of performance indicators on the level of effective coverage
Summarized in a set of radar plots for each of the 43 Sub-Saharan African countries indicators
of case management performance allow for identification of bottlenecks in service provision
along the inputs surveyed. Inefficiencies in service provision appear as a shift on the operation
curve toward the center of the diagram (away from 100% coverage toward 0% at the center of
the diagram) and imply that for a significant proportion of target population the service is fail-
ing to meet the standard of care. For instance in Angola access is the lowest coverage indicator;
once care is sought, however, patients are generally treated appropriately in this country. In
Djibouti access to the first-line antimalarial therapy is the key bottleneck in service provision.
Operational curves for Benin, Cameroon, Central African Republic, and Chad among other re-
veal failures in malaria service delivery along multiple indicators including access, treatment
seeking in formal sector, first-line antimalarial, and drug efficacy.
Overall the drivers of losses in effectiveness are strongly context specific. The impact of dif-
ferent factors can be disentangled by evaluating a series of counterfactual scenarios where the
change in effective coverage is assessed by varying one of the parameters while holding all other
inputs at their baseline values. In Fig 4 we disaggregate the impact of constraints on the overall
effectiveness of treatment using as an example a high malaria burden country of Nigeria. The
outcome of the model- effective coverage- is plotted on the y-axes, labels indicate the estimated
level of effective coverage at lowest and highest values of the parameters (0% and 100%); dash
lines show the level of effective coverage and respective input values at the baseline.
Over 80% of fever cases seek care in Nigeria; yet at such high access to care the effectiveness
of treatment delivered is low- only about a third of treatments result in a cure. Expanding ac-
cess further without addressing inefficiencies in the delivery to 100% of episodes will only in-
crease effective coverage to about 46%. Another dimension- source of treatment- constraint by
access would only raise effective treatment to half of the cases for which care is sought if all
treatments are delivered through the government facilities where presumably high quality
medication is administered by qualified staff based on clinical assessment and providing in-
struction on the appropriate drug regimen. Compliance with the recommended first-line anti-
malarial is particularly low in Nigeria, it is one of the primary reasons for low levels of effective
treatment in the country; about one tenth of episodes for which care is sought are treated ac-
cording to the national guidelines. Focusing policy efforts on compliance will improve effec-
tiveness of malaria case management at the highest rate than changing any other parameter
Fig 4. Impact of Service Parameters on Level of Effective Coverage: Nigeria. Labeled on the x-axis are:
A Access to any care provider; Pf Access to a formal care provider; Da Compliance with the first-line
antimalarial treatment; H Adherence; T Cure rate. Effective coverage. E, evaluated by varying each of the
service indicators from 0 to 100% while holding all other inputs at base value. Values of effective coverage at
lowest and highest values of inputs are labeled on the y-axis to illustrate the sensitivity. Baseline values of
inputs and effective coverage are shown in dash lines.
doi:10.1371/journal.pone.0127818.g004
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considered here; however even at 100% compliance without improvements in other areas sig-
nificant losses to inefficiencies in services delivery will be incurred with only about 63% of fe-
vers treated effectively.
Another way to illustrate this point is by comparing the three sets of maps with color gradi-
ents used to show country levels of access to health services (Fig 5(A)), compliance with the
first-line treatment (Fig 5(Da)), and effective coverage (Fig 5(E)). For the most part effective
coverage appears to follow closely patterns in compliance; high levels of access are offset by
treatment with less efficacious antimalarial regimens. Yet, across countries with low compli-
ance the level of effective treatment is markedly higher in settings where patients seek care and
rely more heavily on formal care providers.
Discussion
Despite the availability of efficacious drugs, the failure to treat malaria fevers effectively proba-
bly contributes much to the still unacceptably high burden of the disease. We estimate coun-
try-level values ranging from 8% to 72% for the effective coverage and from 0.1% to 68% for
systems effectiveness. Effective coverage appears to be particularly low in a cluster of countries
in the central and North Eastern part of the continent including Somalia, South Sudan, Chad,
Ethiopia, Central African Republic and North and South Sudan. Effective treatment of malaria
depends on successful completion of each step in the service delivery path. Failure at any step
means that the infection will be inadequately treated or not treated at all, so all steps in the
chain need to be high if effective coverage is to achieve an acceptable level. Our analysis sug-
gests that there are issues needing to be addressed at each step, but the country level data are
very uncertain. This is mainly because of a lack of country level data on key indicators includ-
ing adherence, quality and resistance of non-ACT antimalarials, on which drugs are used by
care providers, and on the ways in which the available data relate to patient outcomes.
Nationally representative DHS and MICS are the key sources of data on coverage and utili-
zation of malaria control services in endemic countries. While these surveys provide extensive
information on access to care and other coverage indicators, the data collection rounds are
widely spaced; with an average frequency of every 5 years for DHS and 3 years for MICS per
country. In our analysis for about half of the sample, data came from 2011–2012 (S2 Table), for
these countries consistent estimates of access, source of care, compliance and adherence could
be estimated from the DHS. For the remaining countries with less recent DHS data we made
every effort to bring these estimates into the same time horizon by drawing on 2010–2011
MICS and 2012 WMR, albeit at the cost of potentially introducing uncertainty by combining
estimates from different sources with somewhat varying sampling frame, quality, and scope.
Fig 5. Access, First-Line Antimalarial Treatment, and Effective Coverage of Malaria Case
Management by Country. A. Access to any provider; Da Compliance with the first-line antimalarial
treatment; C. Effective coverage. Maps were generated by authors using spmap command[73] in Stata 13
SE; Country coordinates were sourced from Global Administrative Areas (http://gadm.org).
doi:10.1371/journal.pone.0127818.g005
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The level of uncertainty in estimates of effective coverage induced by these data limitations
differs by indicator. The implications for interpretation are two-fold. First the quality of esti-
mates varies by country with more uncertainty around estimates for countries with no recent
DHS surveys. Second these methodological differences may bias comparisons of coverage indi-
cators across settings. To gauge the magnitude of the problem we summarized coverage indica-
tors for a subset of countries with consistent DHS 2011–2012 and found the range and the
median effective coverage estimates for this subset to be nearly identical to that estimated over
the full set of countries; this suggest that while estimates are imprecise for a given setting, dif-
ferences in estimated effectiveness across the region do reflect underlying inefficiencies in ser-
vice delivery rather than data inconsistencies
Field studies of adherence [49–51] are generally not designed to obtain data representative
of the normal behaviour of the population. Patients may be informed in advance of possible
follow-up visits[52–54]; ACTs are often given free of charge after a confirmed malaria diagno-
sis, with counselling by specifically trained staff on administering treatment (dosage, drug
schedule, intake with fatty foods, re-administration of doses) [55,56]. We did not explicitly
consider accuracy of dosing, since analyses that assessed treatment outcomes among patients
that received suboptimal dosage of antimalarial medication found clearance rates similar to
those fully adherent with respect to dosage [57]. Field studies have shown dosing accuracy of
about 80–99% at formal facilities [58–61] and 65–80% accuracy at retail outlets
[49,57,59,62,63] with rates differing by type of antimalarial, formulation, and packaging.
There is abundant recent evidence on the incidence and pervasiveness of counterfeit and
substandard antimalarial medication in the endemic region, so we include drug quality as a
separate indicator in our framework. However there is a clear lack of representative country
level data to inform this parameter. Generalizing from local studies poses a number of difficul-
ties: differences in study design, testing tools, and thresholds against which drug samples are
evaluated further obscure the interpretation, making these estimates of impact on effectiveness
very uncertain [26,27,64]. The inference about the population risk is particularly problematic
as the surveys of drug quality are very often based on convenience samples of providers and do
not relate directly to consumption. Because of the challenge of inferring national level values
from such surveys we assumed one value for drug quality for all 43 countries; by doing so we
failed to capture the extent of variation across the region as suggested by the limited field data.
Furthermore, patient outcomes when treated with counterfeit or otherwise substandard medi-
cations are not well understood. Assuming conservatively that poor quality treatments always
fail might bias our estimates of effective coverage.
Despite the difficulty of working with these sparse data and hence borrowing of information
across countries (which tends to average out the differences), we estimate that there is a sub-
stantial variation between countries in compliance, drug quality, and adherence. A conse-
quence is that the relative importance of these factors also varies between countries. In
contrast, ACT resistance is currently not a significant contributor to loss of systems effective-
ness while resistance to other drugs is an important contributor in the informal sector. Again,
our estimates probably understate the variation between countries, because we lack a compre-
hensive source of accurate and up to date information on resistance to the drugs that are actu-
ally in use. We adopted one threshold value, based on an average level of drug resistance for
SP, for all countries. This does not accurately reflect variation in the level of resistance across
settings because a range of antimalarial therapies aside from SP and the first-line antimalarial
drugs are in circulation. These include artemisinin monotherapies which are likely much more
effective than SP, as well as chloroquine, to which resistance is widespread.
Further the model for service delivery relies on a number of generalizations to assess patient
outcomes along the malaria case management delivery path, something we have addressed
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above by indicator. Given the quality of data our focus here is to present a measure of effective
coverage that could be easily interpreted and estimated with available data rather than to pre-
cisely parameterize clearance rates for malaria case management per se. We effectively ignore
heterogeneity in response to treatment that stems from malaria age-incidence particular to a
given setting, levels of exposure and resistance to antimalarial regimens available in a given
country, the range of antimalarials used, quality of drugs and its distribution across vendors,
response to incomplete drug schedule among other. Constrained by data availability and evi-
dence by imposing linearity in combining coverage indicators to measures of effectiveness of
case management we likely understate the level of clearance achieved with routine care.
In the context of these concerns about data quality especially at country level, it would be
premature to use these estimates to pinpoint specific national systems failings, because so
many of the data are unreliable. We present our findings as point estimates without properly
representing the uncertainty around these parameters, because many of the values depend on
assumptions about generalizability that we cannot test. A conclusion is that there is an urgent
need for improved data on a key essential set of these indicators, especially on provider compli-
ance, adherence and drug quality. Forthcoming work by [65] overcomes some of these limita-
tions relying on econometric and statistical modelling to yield estimates of ACT coverage and
malaria diagnostics for the region. Further on-going efforts on collecting and standardizing
data on quality of antimalarial medication and drug resistance led by WWARN will help in-
form more reliably these key indicators for the region [66,67].
The counterfactual analysis indicates the potential improvement in effective coverage that
could be achieved by improvements in each of these factors, illustrating the constraints that the
downstream factors impose on treatment outcomes. The impact of any given parameter on ef-
fectiveness is scaled by the level other indicators. Compliance, adherence, and cure rates are
more important in settings where access is high. Similarly, in the presence of alternate less ef-
fective treatments adherence and quality of first-line drugs will only have a major impact
where provider compliance is relatively good. For the same underlying statistical reason, with-
in-country heterogeneities (including local inequity in any of the parameters) will also tend to
reduce effectiveness below the estimates we obtain by assigning single national-level values for
each parameter.
In terms of the effects of health systems interventions, expanding access to treatment trans-
lates into higher levels of effective coverage in settings where other service indicators perform
well; switching to a more efficacious treatment regimen can only improve effective coverage if
treatment is sought and the drug is taken. In general policy efforts targeting marginal improve-
ments across multiple dimensions of service provision will result in a greater improvement in
effectiveness than interventions focused on scaling up only one particular aspect of malaria
case management. It follows that analysis of the potential public health impact of improving
each parameter contributing to efficacy needs to consider the values of the other parameters.
Such analysis would also need to consider the impact on the pool of infectious hosts contribut-
ing to malaria transmission, taking into account whether treatment is prompt, which affects
burden both because it modifies the chances of onward transmission, but also because delayed
treatment increases the risk that an uncomplicated episode progresses to a more severe or a
fatal one and[6]. As a consequence of these effects, treatment effectiveness is not only of public
health importance in its own right, but it also modifies the impacts that are achieved by preven-
tive interventions. Effective case management thus needs to be considered as part of an overall
integrated control and elimination strategy, and the potential impacts of both preventive and
curative interventions should be evaluated within an inclusive framework that considers both,
as well as their interactions. Naïve analyses might suggest that different interventions represent
alternative ways of averting the same disease burden, but simulations suggest that the impact
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of some preventive interventions (in particular, long-lasting insecticide nets) could correlate
positively with the quality of curative care [68].
Our analysis does not identify the specific factors directly responsible for low effectiveness
and hence do not suggest specific strategies to address inefficiencies in service delivery. Low
levels of treatment seeking might imply poor allocation and deployment of resources and facili-
ties or reflect population perception of severity of illness or quality of care [16,17,69]. Incidence
of non-compliant treatment on the other hand might point toward problems with governance
and regulatory efforts, the supply system or affordability of the ACT therapy [16,69]. Further
incorrect administration of effective drugs could indicate gaps in knowledge of care providers
and caretakers with respect to appropriate regimen, failure of care providers to communicate
instructions correctly or again point to affordability of treatment [19,49]. Quality of antimalari-
al compounds is another complex dimension that signals broader systems problems on the
legal and enforcement side as well as poor infrastructure and failure to enable proper storage
and handling of medical supplies in endemic settings [26,27,64]. However, the weak correlation
of effective coverage with indices of economic development indicates that resource constraints
are only a small part of the story (S1 Fig). Some countries with relatively strong economies in-
cluding Equatorial Guinea, Gabon, Namibia, Ghana, and North Sudan have low success rates
of treatment for patients that seek care for malaria, even in comparison with much poorer
countries.
In addition to the need for timely and quality data at country level, there will be a need for
improvements to our algorithm to account for non-linearity in metrics and increasing use of
diagnostic tests. Symptomatic treatment remains the norm in most of Africa [22,36,70] and we
implicitly assume care seeking and treatment are independent of the underlying cause of fever.
Increasingly though, malaria treatments are based on parasitological diagnoses and health fa-
cilities surveys found 85% (in Ghana) and 84% (in Benin) of prescriptions to be based on posi-
tive test results[71]. Results from Senegal are similar[72]. Treatment conditional on diagnosis
ensures antimalarials are administered only to patients with the infection. This is particularly
relevant with reductions in transmission which mean that presumptive treatment leads to mas-
sive over-prescription of costly ACT therapy. Incorporation of parasitological diagnosis into
the algorithm would lead to lower estimates of provider compliance with official guidelines,
but should have little effect on estimated effective coverage, since malaria diagnosis mainly im-
proves management of non-malaria fevers.
Overall, our study has highlighted striking gaps in the availability of fundamental data on
the performance of health systems in sub-Saharan Africa, with most of our estimates, except
measures of access, depending on very partial unreliable data with low spatial and temporal
resolution. Further analyses, considering temporal trends, sub-national heterogeneity in access,
and geographical patterns of disease, will make it possible to compare between countries the
potential public health impacts of improving the different indices, alongside the impacts of
other interventions. Although the estimates we have made so far are crude, they already indi-
cate in broad terms where additional data and improvements in systems performance are most
needed.
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